Affinia Therapeutics has announced a significant milestone in the development of its investigational gene therapy, AFTX-201, with the US Food…
Read More
Autobahn Therapeutics Secures FDA Fast Track Designation for Elunetirom in Bipolar Depression
Autobahn Therapeutics has announced a significant milestone in its development of elunetirom, a novel central nervous system (CNS)-directed thyroid hormone…
Read More
VERTANICAL’s Investigational Non-Opioid Chronic Low Back Pain Treatment VER-01 Receives FDA Breakthrough Therapy Designation
VERTANICAL has announced a significant milestone in its development of VER-01, an investigational non-opioid therapeutic candidate for chronic low back…
Read More
Merck & Co. Acquires Terns Pharmaceuticals, Bolstering Chronic Myeloid Leukemia Pipeline with FDA Breakthrough Designation for TERN-701
Merck & Co. (MSD) has successfully completed its acquisition of Terns Pharmaceuticals, a strategic move that significantly enhances MSD’s portfolio…
Read MoreYOU MAY HAVE MISSED
